Eterna Therapeutics Inc (ERNA)

$0.23 -0.02 (-6.24%)
Market Cap 1.43M
Revenue (ttm) 580,000.00
Net Income (ttm) -44.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,679.31%
Debt to Equity Ratio 0.00
Volume 359,085
Avg Vol 12,707,749
Day's Range N/A - N/A
Shares Out 5.41M
Stochastic %K 48%
Beta 4.47
Analysts Hold
Price Target N/A

Company Profile

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. Th...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 798 6700
Address:
1035 Cambridge Street, Suite 18A, Cambridge, United States
Ernexatx
Ernexatx Jul. 29 at 4:21 PM
$ERNA - Building breakthrough therapies through compelling science, independent validation and disciplined execution. ERNA-101 is on track for a Q3 IND submission and first-in-human study in Q4. Following compelling preclinical data, we believe 2026 has the potential to be a significant value creation year. https://www.ernexatx.com/
0 · Reply
PandaTrade_
PandaTrade_ Jul. 28 at 8:11 PM
Seems like Volume is going in to APUS fast now! 🚀 APUS is breaking out with huge NEWS released! Only 400k shares remaining - People are just finding it. Don't be late to APUS, It's going parabolic. $POET $SOUN $ERNA $USO spikere
0 · Reply
smithwaldJR
smithwaldJR Jul. 27 at 10:11 PM
$ERNA getting cheap, probs runs this week
0 · Reply
Ernexatx
Ernexatx Jul. 24 at 1:33 PM
$ERNA CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies https://bit.ly/44LT3JU
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 24 at 1:20 PM
$ERNA Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
0 · Reply
ExploringTrades
ExploringTrades Jul. 23 at 11:21 PM
$ERNA A
0 · Reply
KiserSose
KiserSose Jul. 23 at 8:32 PM
$ERNA how low can you go. Doin' the Limbo rock drop
0 · Reply
CometaMan
CometaMan Jul. 23 at 7:26 PM
$ERNA Doing the Nasty thing 🤮as usual! Another -10, Let's see where this goes AH? lol🐻🤑
0 · Reply
WVU1
WVU1 Jul. 23 at 11:51 AM
$ERNA One can hope it comes back up .
0 · Reply
SuminskiStonks
SuminskiStonks Jul. 23 at 11:17 AM
$ERNA Definitely, being manipulated by investors
0 · Reply
Latest News on ERNA
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies

Jul 24, 2026, 9:20 AM EDT - 7 days ago

Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies

Ernexa Therapeutics announces new ERNA-101 preclinical data

2026-07-15T12:15:21.000Z - 16 days ago

Ernexa Therapeutics announces new ERNA-101 preclinical data

Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry

Jul 15, 2026, 7:50 AM EDT - 16 days ago

Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry

Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026

Jul 14, 2026, 9:01 AM EDT - 17 days ago

Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026

Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients

Jun 25, 2026, 9:15 AM EDT - 5 weeks ago

Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

Jun 17, 2026, 8:47 AM EDT - 6 weeks ago

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer

Jun 9, 2026, 8:41 AM EDT - 7 weeks ago

Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer

Ernexa Therapeutics plans ERNA-101 investigational new drug submission for Q3

2026-05-27T14:06:25.000Z - 2 months ago

Ernexa Therapeutics plans ERNA-101 investigational new drug submission for Q3

Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development

May 27, 2026, 8:11 AM EDT - 2 months ago

Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity

May 20, 2026, 8:31 AM EDT - 2 months ago

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101

May 11, 2026, 9:15 AM EDT - 2 months ago

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101

Ernexa Therapeutics initiated with a Buy at Brookline

2026-05-07T21:58:10.000Z - 3 months ago

Ernexa Therapeutics initiated with a Buy at Brookline

3 Penny Stocks to Watch Now, 5/7/26

2026-05-07T16:17:11.000Z - 3 months ago

3 Penny Stocks to Watch Now, 5/7/26

AHMA PMAX

Ernexa Therapeutics announces new ERNA-101 preclinical data

2026-05-07T04:27:19.000Z - 3 months ago

Ernexa Therapeutics announces new ERNA-101 preclinical data

Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models

May 6, 2026, 8:33 AM EDT - 3 months ago

Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models

Ernexa Therapeutics announces 1-for-25 reverse stock split

2026-04-30T19:19:12.000Z - 3 months ago

Ernexa Therapeutics announces 1-for-25 reverse stock split

Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split

Apr 30, 2026, 9:00 AM EDT - 3 months ago

Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split

Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026

Mar 31, 2026, 8:55 AM EDT - 4 months ago

Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026

Ernexa Therapeutics files $50M mixed securities shelf

2026-03-16T10:56:34.000Z - 4 months ago

Ernexa Therapeutics files $50M mixed securities shelf

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Feb 20, 2026, 9:05 AM EST - 5 months ago

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Ernexa Therapeutics prices 21M shares at 50c in public offering

2026-02-06T14:30:30.000Z - 6 months ago

Ernexa Therapeutics prices 21M shares at 50c in public offering

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

Feb 6, 2026, 9:25 AM EST - 6 months ago

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA

Feb 3, 2026, 8:45 AM EST - 6 months ago

Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA

Ernexa Therapeutics files to sell common stock, warrants, no amount given

2026-02-03T11:21:14.000Z - 6 months ago

Ernexa Therapeutics files to sell common stock, warrants, no amount given

Ernexa selected as company for JETRO Japan entry acceleration program

2026-01-27T13:52:07.000Z - 6 months ago

Ernexa selected as company for JETRO Japan entry acceleration program

Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

Jan 27, 2026, 8:45 AM EST - 6 months ago

Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

Ernexa Therapeutics completes Pre-IND meeting with FDA

2026-01-06T13:38:50.000Z - 7 months ago

Ernexa Therapeutics completes Pre-IND meeting with FDA

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Jan 6, 2026, 8:15 AM EST - 7 months ago

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer

Dec 8, 2025, 8:30 AM EST - 8 months ago

Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer

Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting

Dec 3, 2025, 8:30 AM EST - 8 months ago

Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D.

Dec 2, 2025, 8:50 AM EST - 8 months ago

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D.

Ernexa Therapeutics to Present at Oxford Global's Cell 2025

Nov 11, 2025, 7:00 AM EST - 9 months ago

Ernexa Therapeutics to Present at Oxford Global's Cell 2025

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

Nov 10, 2025, 8:35 AM EST - 9 months ago

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Nov 6, 2025, 9:15 AM EST - 9 months ago

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

Oct 29, 2025, 8:33 AM EDT - 9 months ago

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

Oct 1, 2025, 8:30 AM EDT - 10 months ago

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

Sep 29, 2025, 8:30 AM EDT - 10 months ago

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

Sep 17, 2025, 8:30 AM EDT - 11 months ago

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

Sep 10, 2025, 8:30 AM EDT - 11 months ago

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:30 AM EDT - 11 months ago

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Jun 25, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

Jun 24, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

Jun 10, 2025, 9:30 AM EDT - 1 year ago

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

May 28, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

May 14, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference

May 8, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Apr 22, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Ernexa Therapeutics Closes New Funding Round

Apr 3, 2025, 8:55 AM EDT - 1 year ago

Ernexa Therapeutics Closes New Funding Round

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Feb 26, 2025, 8:30 AM EST - 1 year ago

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Jan 14, 2025, 8:30 AM EST - 1 year ago

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Jan 9, 2025, 7:30 AM EST - 1 year ago

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Nov 14, 2024, 8:30 AM EST - 1 year ago

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

Oct 17, 2024, 8:00 AM EDT - 1 year ago

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

May 10, 2024, 8:00 AM EDT - 2 years ago

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

May 8, 2024, 9:31 AM EDT - 2 years ago

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Feb 20, 2024, 8:30 AM EST - 2 years ago

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Jan 3, 2024, 4:15 PM EST - 2 years ago

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

Dec 20, 2023, 4:15 PM EST - 2 years ago

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

Ernexatx
Ernexatx Jul. 29 at 4:21 PM
$ERNA - Building breakthrough therapies through compelling science, independent validation and disciplined execution. ERNA-101 is on track for a Q3 IND submission and first-in-human study in Q4. Following compelling preclinical data, we believe 2026 has the potential to be a significant value creation year. https://www.ernexatx.com/
0 · Reply
PandaTrade_
PandaTrade_ Jul. 28 at 8:11 PM
Seems like Volume is going in to APUS fast now! 🚀 APUS is breaking out with huge NEWS released! Only 400k shares remaining - People are just finding it. Don't be late to APUS, It's going parabolic. $POET $SOUN $ERNA $USO spikere
0 · Reply
smithwaldJR
smithwaldJR Jul. 27 at 10:11 PM
$ERNA getting cheap, probs runs this week
0 · Reply
Ernexatx
Ernexatx Jul. 24 at 1:33 PM
$ERNA CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies https://bit.ly/44LT3JU
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 24 at 1:20 PM
$ERNA Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
0 · Reply
ExploringTrades
ExploringTrades Jul. 23 at 11:21 PM
$ERNA A
0 · Reply
KiserSose
KiserSose Jul. 23 at 8:32 PM
$ERNA how low can you go. Doin' the Limbo rock drop
0 · Reply
CometaMan
CometaMan Jul. 23 at 7:26 PM
$ERNA Doing the Nasty thing 🤮as usual! Another -10, Let's see where this goes AH? lol🐻🤑
0 · Reply
WVU1
WVU1 Jul. 23 at 11:51 AM
$ERNA One can hope it comes back up .
0 · Reply
SuminskiStonks
SuminskiStonks Jul. 23 at 11:17 AM
$ERNA Definitely, being manipulated by investors
0 · Reply
Cliffx
Cliffx Jul. 23 at 4:57 AM
$ERNA I wouldn't blame $ERNA ..blame the pump..These are just momentum plays...nothing to do with the stock.
0 · Reply
WVU1
WVU1 Jul. 23 at 12:07 AM
$ERNA F**king scam company don't care about it's investors.
0 · Reply
2pumps1dump
2pumps1dump Jul. 21 at 10:38 PM
$ERNA adding. F t mf.
0 · Reply
WVU1
WVU1 Jul. 21 at 8:05 PM
$ERNA What a F**king mess and hope this goes back up.
0 · Reply
KiserSose
KiserSose Jul. 21 at 7:27 PM
$ERNA shorting this stock now would be a liability. Buying now with such a low float is a better idea.
0 · Reply
CometaMan
CometaMan Jul. 21 at 3:16 PM
$ERNA Wow, what an ugly piece of stock! It is nasty! From $14 to $4.48 in just a few days! How unfortunate for those holding ! It is Nasty, Nasty, Nasty! Should I even risk it by loading this ticker under $4.67?🤑 Should I be short or long at this levels? What do you think? 🐻
0 · Reply
rnrsly
rnrsly Jul. 21 at 2:29 PM
$ERNA why crashing so bad? Float is only 668.72K
0 · Reply
WVU1
WVU1 Jul. 21 at 2:22 PM
$ERNA Man hard to watch IM DOWN BIG G NOW SHAME ON ME BUYING THIS POS.
0 · Reply
haily_haily
haily_haily Jul. 21 at 2:02 PM
$ERNA ohh man
0 · Reply
WVU1
WVU1 Jul. 21 at 12:38 AM
$ERNA Unreal shorts will have to cover soon.
0 · Reply
CometaMan
CometaMan Jul. 20 at 6:50 PM
$ERNA I am just looking at this nasty ugly thing going from really ugly to unbearable uglier. How low she has fallen, she looks very unattractive. however, to her merit, the lower she gets, she may become enticing for re-entry.🤑
0 · Reply